Drug Screening Assays, Antitumor
"Drug Screening Assays, Antitumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Descriptor ID |
D004354
|
MeSH Number(s) |
E01.370.225.500.388 E05.200.500.388 E05.242.417 E05.337.550.200
|
Concept/Terms |
Drug Screening Assays, Antitumor- Drug Screening Assays, Antitumor
- Antitumor Drug Screening Assays
- Cancer Drug Tests
- Cancer Drug Test
- Drug Test, Cancer
- Drug Tests, Cancer
- Test, Cancer Drug
- Tests, Cancer Drug
- Drug Screening Tests, Tumor-Specific
- Drug Screening Tests, Tumor Specific
- Antitumor Drug Screens
- Antitumor Drug Screen
- Drug Screen, Antitumor
- Drug Screens, Antitumor
- Screen, Antitumor Drug
- Screens, Antitumor Drug
- Anti-Cancer Drug Screens
- Anti Cancer Drug Screens
- Anti-Cancer Drug Screen
- Drug Screen, Anti-Cancer
- Drug Screens, Anti-Cancer
- Screen, Anti-Cancer Drug
- Screens, Anti-Cancer Drug
- Anticancer Drug Sensitivity Tests
- Tumor-Specific Drug Screening Tests
- Tumor Specific Drug Screening Tests
|
Below are MeSH descriptors whose meaning is more general than "Drug Screening Assays, Antitumor".
Below are MeSH descriptors whose meaning is more specific than "Drug Screening Assays, Antitumor".
This graph shows the total number of publications written about "Drug Screening Assays, Antitumor" by people in this website by year, and whether "Drug Screening Assays, Antitumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 1 | 1 |
1999 | 0 | 2 | 2 |
2001 | 0 | 2 | 2 |
2002 | 0 | 1 | 1 |
2004 | 0 | 3 | 3 |
2005 | 0 | 6 | 6 |
2006 | 2 | 0 | 2 |
2007 | 0 | 2 | 2 |
2008 | 0 | 3 | 3 |
2009 | 0 | 3 | 3 |
2010 | 0 | 2 | 2 |
2011 | 0 | 4 | 4 |
2012 | 0 | 2 | 2 |
2013 | 1 | 1 | 2 |
2014 | 0 | 8 | 8 |
2015 | 0 | 3 | 3 |
2016 | 0 | 3 | 3 |
2017 | 0 | 2 | 2 |
2018 | 0 | 4 | 4 |
2019 | 0 | 4 | 4 |
2020 | 1 | 9 | 10 |
2021 | 0 | 4 | 4 |
2023 | 0 | 1 | 1 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Screening Assays, Antitumor" by people in Profiles.
-
Chemoreactive 2,5-Diketopiperazines from a Penicillium sp., Structure Revision of Reported Analogues and Proposed Facile Transformation Pathways. J Nat Prod. 2024 Jul 26; 87(7):1826-1837.
-
Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer. Eur J Med Chem. 2024 Sep 05; 275:116598.
-
Carbohydrate-Small Molecule Hybrids as Lead Compounds Targeting IL-6 Signaling. Molecules. 2023 Jan 09; 28(2).
-
Synthesis of 3-N-/O-/S-methyl-imidazo[1,2-a] pyridine derivatives for caspase-3 mediated apoptosis induced anticancer activity. Bioorg Chem. 2022 08; 125:105882.
-
Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer. ACS Appl Mater Interfaces. 2021 Oct 27; 13(42):49614-49630.
-
Identification of natural product modulators of Merkel cell carcinoma cell growth and survival. Sci Rep. 2021 06 30; 11(1):13597.
-
Light-assisted anticancer photodynamic therapy using porphyrin-doped nanoencapsulates. J Photochem Photobiol B. 2021 Jul; 220:112209.
-
Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Bioorg Med Chem. 2021 04 01; 35:116061.
-
Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers. Bioorg Chem. 2021 02; 107:104595.
-
OCTAD: an open workspace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features. Nat Protoc. 2021 02; 16(2):728-753.